Rimadyl LA

Rimadyl LA is an aqueous formulation containing carprofen, a non-steriodal, anti-inflammatory drug (NSAID) with analgesic and antipyretic properties for use in cattle and horses in combination with antibiotic therapy, as appropriate.

As with other NSAIDs the exact mode of action of carprofen has not been defined. Carprofen is a reversible inhibitor of cyclo-oxygenase and a moderate inhibitor of phospholipase A2. It has a minimal effect on those prostaglandins that are necessary for the integrity of gastrointestinal tract and renal functions.

Cattle: Rimadyl LA is indicated for the treatment of conditions characterised by inflammation including clinical signs associated with acute mastitis and respiratory disease. In respiratory disease, studies have demonstrated that carprofen has an anti-pyretic effect and significantly improves the pattern of respiration.

Horses: Rimadyl LA is indicated for the treatment of conditions such as musculoskeletal disorders and anti-inflammatory treatment after surgery.

It is necessary to determine the cause of the disease and treat as required with the appropriate antibiotic.

Nil Milk Withhold: Painful conditions can be managed with a single injection of Rimadyl LA without the risk of failing to withhold milk.

Proven Safety: In clinical studies in cattle, the product was well tolerated at up to 5 times the recommended dosage after intravenous or subcutaneous administration¹. In a clinical study in horses, the product was well tolerated at up to 3 times the recommended dose daily for 5 consecutive days after intravenous administration¹.

Proven efficacy for pain control: Rimadyl LA has been proven to reduce pain in a study² in cows with acute mastitis.

Proven efficacy for inflammation control: Rimadyl LA has been proven to reduce inflammation in cattle. A reduction in inflammation aids in control of permanent tissue damage.

Longest Serum Half Life: Rimadyl LA has the longest serum half life of all NSAIDs registered for use in cattle^3-7.

Longer lasting clinical efficacy: In a field trial⁸ of Bovine respiratory disease it has been demonstrated that a single injection of Rimadyl LA is as effective as 3 days treatment with Flunixin.

Rimadyl LA is a clear, sterile, aqueous solution for injection, containing 50mg/mL carprofen.

Rimadyl LA is packed in 50 mL multi-dose amber glass vials.

Cattle: The recommended dose is 1.4 mg/kg (1mL/35 kg) bodyweight by subcutaneous or intravenous injection as a single dose.

Withholding period:       Milk - Nil             Meat - 28 days

Horses: The recommended dose is 0.7 mg/kg (1mL/70 kg) bodyweight intravenous injection only. This can be repeated once after 24hrs.

Withholding period:       Meat – 30 days

Store in a cool, dry, well-ventilated area. Store below 25 °C (Room Temperature). Protect from light. Once broached, product is stable for use at temperatures up to 25°C for 28 days. Following withdrawal of the first dose, use the remainder within 28 days. Discard unused material.

• For intravenous use only in the horse.
• Do not administer by intramuscular injection.
• Do not exceed the stated dose or the duration of treatment.
• Do not administer other NSAIDs concurrently or within 24 hours of each other.
• Like some NSAIDs, carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
• Do not use in animals suffering from cardiac, hepatic or renal disease, or where there is a possibility of gastro-intestinal ulceration, bleeding or hypersensitivity to the product.
• Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
• Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a potential risk of increased renal toxicity.
• Do not use where there is evidence of blood dyscrazias.
• Concurrent administration of potential nephrotoxic drugs should be avoided.
• In the absence of any specific studies in pregnant horses, such use is not indicated.
• NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with baterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. RIMADYL is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A9897. RVM; Available only under Veterinary Authorisation.

References:

1. ACVM approved label text.
2. F. Vangroenweghe et al; Effect of carprofen following experimentally induced E coli mastitis in primiarous cows. Journal of Dairy Science, 2005, 88; 2361-2376.
3. Ludwig, B et al; Carprofen in veterinary medicine. Plasma disposition, milk excretion and tolerance in milk producing cows. Schweiz. Arch. Tierheilk. 1989. 131, 99-106.
4. EMEA. The European agency for the evaluation of medicinal products. Meloxicam. 1997.
5. Tolfedine CS Product Label ACVM No. A007321.
6. Flunix Product label ACVM No. A6404.
7. http://www.vmd.gov.uk. Summary of Product Characteristics Comporion Vet.
8. T.V. Balmer, P. Williams, I.E. Selmans; Comparison of Carprofen and Flunixin Meglumine as Adjunctive Therapy in Bovine Respiratory Disease; The Veterinary Journal 1997, 154, 233-241.

For technical enquiries please phone Zoetis Technical Services on 0800 650 277.

• Zoetis Safety Data Sheets
• Label: http://www.foodsafety.govt.nz/